Core Insights - Elicio Therapeutics received a positive recommendation from the Independent Data Monitoring Committee (IDMC) to continue the ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications, indicating preliminary efficacy signals [2][8] - The final analysis focused on disease-free survival (DFS) is expected in Q4 2025, with plans to advance to a pivotal Phase 3 trial following the analysis [2][8] - The company secured $10 million in financing in Q2 2025, extending its cash runway into Q1 2026, beyond the anticipated final DFS analysis [2][7] Recent Highlights - The R&D expense for Q2 2025 was $7.0 million, a decrease from $8.2 million in Q2 2024, primarily due to reduced clinical trial manufacturing [4] - General and administrative expenses increased to $3.1 million in Q2 2025 from $2.7 million in Q2 2024, attributed to higher professional fees related to financing [5] - The net loss for Q2 2025 was $10.6 million, compared to $7.2 million in Q2 2024, with a net loss per share of $0.66 versus $0.64 in the prior year [6] Financial Position - As of June 30, 2025, cash and cash equivalents were $22.1 million, an increase from $17.6 million at the end of 2024 [10] - Total current assets amounted to $22.6 million, while total liabilities were $27.7 million, resulting in total stockholders' equity of $1.8 million [10] Upcoming Milestones - The company anticipates the DFS event-driven final analysis of the Phase 2 AMPLIFY-7P clinical trial in Q4 2025 [8] - Following the final analysis, Elicio plans to request an End-of-Phase 2 meeting with the FDA to finalize the regulatory strategy for the pivotal Phase 3 trial of ELI-002 [2][8]
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates